Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Cattaneo

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Journal of Drugs in Dermatology : JDD|August 10, 2022
Single-Centre Real-Life Experience of Guselkumab in Patients with Moderate-to-Severe Plaque PsoriasisDario Marletta, Giulia Murgia, Angelo Cattaneo, et al.
Photodermatology, Photoimmunology & Photomedicine|May 3, 2012
Tomesa balneophototherapy in mild to severe psoriasis: a retrospective clinical trial in 174 patientsAngelo Cattaneo, Silvia Alberti Violetti, Simona Tavecchio, et al.
Archives of Dermatological Research|August 8, 2012
Not simply a matter of psoriatic arthritis: epidemiology of rheumatic diseases in psoriatic patientsGabriele De Marco, Angelo Cattaneo, Norma Battafarano, et al.
Drug Development Research|November 11, 2014
The EPIPSOFIRE project: a preliminary reportGabriele De Marco, Angelo Cattaneo, Carlo G Carrera, et al.
The Australasian Journal of Dermatology|July 25, 2022
Three cases of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by proton-pump inhibitorsCristina B Spigariolo, Francesca Barei, Carlo A Maronese, et al.
Lupus|June 11, 2024
Belimumab-induced periungual pyogenic granulomas: A case reportCecilia Beatrice Chighizola, Ilaria Suardi, Achille Marino, et al.
The Journal of Dermatological Treatment|October 24, 2017
PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasisCarlo Giovanni Carrera, Paolo Dapavo, Piergiorgio Malagoli, et al.
International Journal of Molecular Sciences|December 23, 2023
A Multidisciplinary Approach to Patients with Psoriasis and a History of Malignancies or On-Treatment for Solid Tumors: A Narrative Literature ReviewNerina Denaro, Gianluca Nazzaro, Giulia Murgia, et al.
Journal of Drugs in Dermatology : JDD|December 21, 2020
Predicting Secukinumab Fast-Responder Profile in Psoriatic Patients: Advanced Application of Artificial-Neural-Networks (ANNs)Giovanni Damiani, Rosalynn R Z Conic, Paolo D M Pigatto, et al.
Clinical and Experimental Rheumatology|October 31, 2024
A new instrument for the screening of psoriatic arthritis among psoriatic patientsGabriele De Marco, Antonio Marchesoni, Maria Manara, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Drugs in Dermatology : JDD|August 10, 2022
Single-Centre Real-Life Experience of Guselkumab in Patients with Moderate-to-Severe Plaque PsoriasisDario Marletta, Giulia Murgia, Angelo Cattaneo, et al.
Photodermatology, Photoimmunology & Photomedicine|May 3, 2012
Tomesa balneophototherapy in mild to severe psoriasis: a retrospective clinical trial in 174 patientsAngelo Cattaneo, Silvia Alberti Violetti, Simona Tavecchio, et al.
Archives of Dermatological Research|August 8, 2012
Not simply a matter of psoriatic arthritis: epidemiology of rheumatic diseases in psoriatic patientsGabriele De Marco, Angelo Cattaneo, Norma Battafarano, et al.
Drug Development Research|November 11, 2014
The EPIPSOFIRE project: a preliminary reportGabriele De Marco, Angelo Cattaneo, Carlo G Carrera, et al.
The Australasian Journal of Dermatology|July 25, 2022
Three cases of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by proton-pump inhibitorsCristina B Spigariolo, Francesca Barei, Carlo A Maronese, et al.
Lupus|June 11, 2024
Belimumab-induced periungual pyogenic granulomas: A case reportCecilia Beatrice Chighizola, Ilaria Suardi, Achille Marino, et al.
The Journal of Dermatological Treatment|October 24, 2017
PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasisCarlo Giovanni Carrera, Paolo Dapavo, Piergiorgio Malagoli, et al.
International Journal of Molecular Sciences|December 23, 2023
A Multidisciplinary Approach to Patients with Psoriasis and a History of Malignancies or On-Treatment for Solid Tumors: A Narrative Literature ReviewNerina Denaro, Gianluca Nazzaro, Giulia Murgia, et al.
Journal of Drugs in Dermatology : JDD|December 21, 2020
Predicting Secukinumab Fast-Responder Profile in Psoriatic Patients: Advanced Application of Artificial-Neural-Networks (ANNs)Giovanni Damiani, Rosalynn R Z Conic, Paolo D M Pigatto, et al.
Clinical and Experimental Rheumatology|October 31, 2024
A new instrument for the screening of psoriatic arthritis among psoriatic patientsGabriele De Marco, Antonio Marchesoni, Maria Manara, et al.
Pageof 2